Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
$33.95
-$0.14(-0.65%)
At close: 4:00 PM EST
$33.95
-$0.14(-0.65%)
Day’s Range― - ―
52-Week Range$17.24 - $34.30
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.42M
Market Cap
$20.97B
Enterprise Value$15.77B
Total Cash (Recent Filing)$3.41B
Total Debt (Recent Filing)$142.00M
Price to Earnings (P/E)14.3
Beta0.50
Next Earnings
Feb 05, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding642,384,100
10 Day Avg. Volume1,484,635
30 Day Avg. Volume1,419,230
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.65
Price to Sales (P/S)4.51
P/FCF Ratio12.81
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue1.12
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda2.64
Forecast
1Y Price Target
$38.40Price Target Upside13.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Potential And Formulation StrategyDevelopment of a subcutaneous petosemtamab formulation and Epkinly's feasibility for outpatient administration increase patient convenience and could accelerate market uptake across multiple indications.
Late-stage Clinical CatalystsPending pivotal and Phase III readouts for Rina-S, Epkinly in frontline lymphoma, and petosemtamab in head and neck cancer create a steady stream of binary events that could materially re-rate the stock.
Regulatory ApprovalsFDA approvals expanding Epkinly's label in follicular lymphoma broaden the addressable patient population and support wider commercial adoption.
Bears Say
Acquisition And Financing DilutionPlanned acquisition activity, while expected to be accretive over time, is likely to be highly dilutive to per-share metrics in the early years after closing, pressuring near-term valuation.
Clinical Trial Survival RiskDeterioration in overall survival observed with acasunlimab raises concern about Phase III success probability and could weigh on investor confidence in related programs.
Outcome UnpredictabilityHigh response rates reported in biomarker-unselected populations create uncertainty around how real-world treatment patterns will emerge, complicating forecasting of future market share.
Genmab News
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $17.23 and its highest was $34.30 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $20.97B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Feb 05, 2026 which is in 22 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Nov 10, 2025. The company reported $0.646 earnings per share for the quarter, beating the consensus estimate of $0.486 by $0.16.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.43.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 642,384,100 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.646 in its last earnings report, beating expectations of $0.486. Following the earnings report the stock price went up 1.396%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.40 (13.11% Upside)
$38.40 (13.11% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 15.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 4.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.27%
12-Months-Change
Fundamentals
Return on Equity
28.20%
Trailing 12-Months
Asset Growth
18.25%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
GMAB Company Deck
GMAB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, a solid financial position, and strategic advancements with the proposed acquisition of Merus. However, there were some challenges, including the termination of GEN1042 development in head and neck cancer and a sales miss for EPKINLY. Overall, the positives of strong financial performance and strategic growth initiatives outweigh the negatives.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$38.40
▲(13.11% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.81% Mutual Funds
0.02% Other Institutional Investors
98.21% Public Companies and Individual Investors